XML 52 R40.htm IDEA: XBRL DOCUMENT v3.26.1

Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated

Net loss for our reportable segment is as follows (in thousands):

			Three Months Ended June 30,												Six Months Ended June 30,
			2026						2025						2026						2025
Total revenue			$	51,240					$	26,425					$	95,446					$	42,942
Cost of sales			298						136						536						194
Gross profit			50,942						26,289						94,910						42,748
Operating expenses
External research and development expense (including    amounts with related parties) (1)			10,424						8,552						30,506						14,063
Internal research and development expense (including    amounts with related parties): (2)
Personnel-related costs			26,602						23,632						52,452						46,697
Equipment, depreciation, and facility costs			13,410						13,111						26,998						26,303
Other research and development costs			10,380						9,941						18,849						16,407
Total internal research and development expense			50,392						46,684						98,299						89,407
Total research and development expense (including    amounts with related parties)			60,816						55,236						128,805						103,470
Selling, general and administrative (including    amounts with related parties)			51,823						42,338						97,593						74,992
Total operating expenses			112,639						97,574						226,398						178,462
Loss from operations			(61,697)						(71,285)						(131,488)						(135,714)
Other income (expense), net
Interest and investment income, net			3,155						1,153						5,469						2,040
Change in fair value of related-party convertible note			(95,964)						1,169						(332,589)						(41,413)
Change in fair value of warrant liabilities			(44,190)						3,889						(339,603)						3,441
Interest expense related to revenue interest liability			(17,192)						(13,405)						(31,063)						(26,939)
Interest expense (including amounts with related parties)			(14,052)						(15,479)						(28,645)						(30,810)
Change in fair value of derivative liabilities			(692)						1,931						416						7,509
Other income (expense), net			242						(278)						(5,675)						(319)
Total other expense, net			(168,693)						(21,020)						(731,690)						(86,491)
Loss before income taxes and noncontrolling interests			(230,390)						(92,305)						(863,178)						(222,205)
Income tax expense			—						(269)						(9)						(35)
Net loss			(230,390)						(92,574)						(863,187)						(222,240)
Net loss attributable to noncontrolling interests, net of tax			(12)						(19)						(27)						(39)
Net loss attributable to ImmunityBio common stockholders			$	(230,378)					$	(92,555)					$	(863,160)					$	(222,201)

_______________

(1)			Our external research and development expense supports our various preclinical and clinical programs.
(2)			Our internal research and development expense includes payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of our research and development activities.

Schedule of Revenue by Geographic Region

We generate a portion of our revenues from outside of the U.S. Information about our revenue by geographic region is as follows (in thousands):

			Three Months Ended June 30,												Six Months Ended June 30,
			2026						2025						2026						2025
U.S.			$	50,722					$	26,425					$	94,904					$	42,942
Europe			518						—						542						—
Total segment revenue			$	51,240					$	26,425					$	95,446					$	42,942

X

- Definition

Tabular disclosure of reconciliation of profit (loss) by reportable segment to consolidated profit (loss). Includes, but is not limited to, reconciliation of income (loss) before income tax expense (benefit) and after income tax if income tax is allocated to reportable segment.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue attributed to country of domicile and foreign country from which revenue is derived if it is not provided as part of reportable segment information. Includes, but is not limited to, subtotal of geographical information about group of countries.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration